Different Skeletal Effects of the Peroxisome Proliferator Activated Receptor (PPAR)alpha Agonist Fenofibrate and the PPARgamma Agonist Pioglitazone

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2009 Apr 1

PMID 19331671

Citations 38

Authors

Unni Syversen

Astrid K Stunes

Bjorn I Gustafsson

Karl J Obrant

Lars Nordsletten

Rolf Berge

Liv Thommesen

Janne E Reseland

Affiliations

Soon will be listed here.

Abstract

Background: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARgamma agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treated for type 2 diabetes mellitus. The aim of the study was to examine the effect of the PPARalpha agonist fenofibrate (FENO) and the PPARgamma agonist pioglitazone (PIO) on bone in intact female rats.

Methods: Rats were given methylcellulose (vehicle), fenofibrate or pioglitazone (35 mg/kg body weight/day) by gavage for 4 months. BMC, BMD, and body composition were measured by DXA. Histomorphometry and biomechanical testing of excised femurs were performed. Effects of the compounds on bone cells were studied.

Results: The FENO group had higher femoral BMD and smaller medullary area at the distal femur; while trabecular bone volume was similar to controls. Whole body BMD, BMC, and trabecular bone volume were lower, while medullary area was increased in PIO rats compared to controls. Ultimate bending moment and energy absorption of the femoral shafts were reduced in the PIO group, while similar to controls in the FENO group. Plasma osteocalcin was higher in the FENO group than in the other groups. FENO stimulated proliferation and differentiation of, and OPG release from, the preosteoblast cell line MC3T3-E1.

Conclusion: We show opposite skeletal effects of PPARalpha and gamma agonists in intact female rats. FENO resulted in significantly higher femoral BMD and lower medullary area, while PIO induced bone loss and impairment of the mechanical strength. This represents a novel effect of PPARalpha activation.

Citing Articles

A realistic mixture of ubiquitous persistent organic pollutants affects bone and cartilage development in zebrafish by interaction with nuclear receptor signaling.

Guerrero-Limon G, Zappia J, Muller M PLoS One. 2024; 19(3):e0298956.

PMID: 38547142 PMC: 10977810. DOI: 10.1371/journal.pone.0298956.

Association between dietary macronutrient composition and plasma one-carbon metabolites and B-vitamin cofactors in patients with stable angina pectoris.

Bratveit M, Van Parys A, Olsen T, Strand E, Marienborg I, Laupsa-Borge J Br J Nutr. 2024; 131(10):1678-1690.

PMID: 38361451 PMC: 11063666. DOI: 10.1017/S0007114524000473.

Rescuing SERCA2 pump deficiency improves bone mechano-responsiveness in type 2 diabetes by shaping osteocyte calcium dynamics.

Shao X, Tian Y, Liu J, Yan Z, Ding Y, Hao X Nat Commun. 2024; 15(1):890.

PMID: 38291059 PMC: 10828510. DOI: 10.1038/s41467-024-45023-6.

Causal relationship between type 2 diabetes mellitus and bone mineral density: a Mendelian randomization study in an East Asian population.

Huang G, Chen X, Chen Y, Liu W, Chen C, Song W Osteoporos Int. 2023; 34(10):1719-1727.

PMID: 37306802 PMC: 10511588. DOI: 10.1007/s00198-023-06807-6.

Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging.

Murata Y, Kataoka Y, Asaumi Y, Noguchi T Cardiovasc Diagn Ther. 2023; 13(1):100-108.

PMID: 36864976 PMC: 9971301. DOI: 10.21037/cdt-22-401.

References

Saltiel A, Olefsky J . Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996; 45(12):1661-9. DOI: 10.2337/diab.45.12.1661. View

Schoonjans K, Martin G, Staels B, Auwerx J . Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997; 8(3):159-66. DOI: 10.1097/00041433-199706000-00006. View

De Souza C, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D . Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001; 50(8):1863-71. DOI: 10.2337/diabetes.50.8.1863. View

Damci T, Tatliagac S, Osar Z, Ilkova H . Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med. 2004; 14(6):357-360. DOI: 10.1016/s0953-6205(03)90001-x. View

Lee S, Lorenzo J . Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology. 1999; 140(8):3552-61. DOI: 10.1210/endo.140.8.6887. View

Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, Lamas S, Perez-Sala D . PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines. J Am Soc Nephrol. 2002; 13(9):2223-31. DOI: 10.1097/01.asn.0000025786.87646.b1. View

Kliewer S, Xu H, Lambert M, Willson T . Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001; 56:239-63. DOI: 10.1210/rp.56.1.239. View

Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J . Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005; 331(2):520-6. DOI: 10.1016/j.bbrc.2005.03.210. View

de Vos P, Lefebvre A, Miller S, Guerre-Millo M, Wong K, Saladin R . Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest. 1996; 98(4):1004-9. PMC: 507516. DOI: 10.1172/JCI118860. View

10.

Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z . Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens. 2007; 20(2):206-10. DOI: 10.1016/j.amjhyper.2006.08.002. View

11.

Yaturu S, Bryant B, Jain S . Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007; 30(6):1574-6. DOI: 10.2337/dc06-2606. View

12.

Naderali E, Fatani S, Williams G . Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. Atherosclerosis. 2004; 177(2):307-12. DOI: 10.1016/j.atherosclerosis.2004.07.029. View

13.

Riera-Guardia N, Rothenbacher D . The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab. 2007; 10(5):367-75. DOI: 10.1111/j.1463-1326.2007.00755.x. View

14.

Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N . Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23(3):323-30. View

15.

Jackson S, Demer L . Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 2000; 471(1):119-24. DOI: 10.1016/s0014-5793(00)01372-7. View

16.

Grey A . Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2007; 19(2):129-37. DOI: 10.1007/s00198-007-0477-y. View

17.

Richards J, Valdes A, Burling K, Perks U, Spector T . Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007; 92(4):1517-23. DOI: 10.1210/jc.2006-2097. View

18.

Reid I, Cornish J, Baldock P . Nutrition-related peptides and bone homeostasis. J Bone Miner Res. 2006; 21(4):495-500. DOI: 10.1359/jbmr.051105. View

19.

Schwartz A, Sellmeyer D, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold K . Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; 91(9):3349-54. PMC: 1563497. DOI: 10.1210/jc.2005-2226. View

20.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View